Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05445440 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT05445440 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 30 participants.
The verdict
NCT05445440, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of BMS-986371 on the drug levels of methotrexate, sulfasalazine and their main metabolites in healthy male adult participants.
Interventions
- DRUG Leucovorin
- DRUG Methotrexate
- DRUG Sulfasalazine
- DRUG BMS-986371
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-09-06 |
| Est. Completion | 2022-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05445440
The ClinicalTrials.gov registry entry for NCT05445440 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Leucovorin is the first listed.
NCT05445440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05445440 about?
NCT05445440 is a clinical study titled "A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine". The purpose of this study is to evaluate the effects of BMS-986371 on the drug levels of methotrexate, sulfasalazine and their main metabolites in healthy male adult participants.
What is the current status of trial NCT05445440?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-09-06. Estimated completion is 2022-11-23.
What interventions are being tested in trial NCT05445440?
The interventions under investigation include: Leucovorin (DRUG), Methotrexate (DRUG), Sulfasalazine (DRUG), BMS-986371 (DRUG).
Who is sponsoring clinical trial NCT05445440?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.